Roche has signed a share purchase agreement to acquire 100% of the outstanding shares of TIB Molbiol Group. Closing of the transaction is subject to customary closing conditions and is expected in the fourth quarter of 2021.
The acquisition of TIB Molbiol Group will expand Roche’s broad portfolio of molecular diagnostic solutions to include a variety of assays for infectious diseases, such as the identification of SARS-CoV-2 variants. TIB Molbiol’s portfolio of more than 45 CE-IVD assays and more than 100 assays for research purposes is already available on Roche’s large installed base of LightCycler PCR systems and MagNA Pure sample preparation systems. The two companies have been working together for more than 20 years.
TIB Molbiol was founded over 30 years ago. As a manufacturer of custom oligonucleotides, it has participated in the development of molecular diagnostics and built a broad portfolio of diagnostic assays. Most assays are used to test for infectious diseases. They are available as modular kits. This means that symptomatic panels can be created by combining assays. To support customers performing human genotyping, TIB Molbiol provides custom-made LightSNiP assays for SNP analysis.